Premium
P1‐155: DIFFERENCES IN THE AMYLOID PLAQUE PROTEOME IN DOWN SYNDROME
Author(s) -
Drummond Eleanor,
Berdah Valentin,
Nayak Shruti,
Pires Geoffrey,
Ueberheide Beatrix,
Wisniewski Thomas
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.710
Subject(s) - neuropathology , proteome , proteomics , biology , amyloid (mycology) , neurodegeneration , immunohistochemistry , alzheimer's disease , pathology , disease , neuroscience , microbiology and biotechnology , medicine , bioinformatics , biochemistry , gene
model mice. Results: We were able to observe a robust increase in Plk2 staining in AD patient hippocampal tissue samples that was not seen in regions of the brain unaffected by AD (cerebellum and occipital lobe). Treatment with both Plk inhibitors resulted in a significant decrease in Ab levels in AD mouse brains. Conclusions: These experiments suggest that Plk2 may be a key regulator in promoting hyperactivity and the generation and secretion of Ab in early AD, and may therefore be a promising target for patient intervention.